RCKT Q4 2021 Earnings — Rocket Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RCKTRocket Pharmaceuticals, Inc.

$572M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$44M

Net Income

-$44M

EPS (Diluted)

$-0.69

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$33M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$497M

Total Liabilities

$42M

Stockholders' Equity

$455M

Cash & Equivalents

$233M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$44M	-$59M	+25.2%
Net Income	-$44M	-$61M	+27.4%